The FDA is moving away from requiring animal models for investigational new drug (IND) applications for new monoclonal ...

Certara’s AI strategy and FDA-aligned offerings fuel growth across drug discovery and trials, with expanding margins. Read ...

Late Thursday, the US Food and Drug Administration revealed it is taking a ground-breaking step to advance public health by ...

The U.S. Food and Drug Administration is replacing animal testing with human-relevant methods, including artificial ...

Human-Based Lab Models: The FDA will promote the use of lab-grown human “organoids” and organ-on-a-chip systems that mimic ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

The U.S. Food and Drug Administration said on Thursday it plans to replace animal testing in the development of monoclonal ...

As the last of the anti-CGRP mAbs to enter the migraine market, Vyepti has seen moderate uptake since its FDA approval.

Numerous treatment options for COVID-19 have been approved by the U.S. Food and Drug Administration over the last four years, ...

The global antibody market is poised for remarkable expansion over the next decade, with market estimates predicting a significant rise in valuation from USD 266.83 billion in 2024 to an impressive ...

The U.S. Food and Drug Administration is replacing animal testing in the development of monoclonal antibody therapies and other drugs with ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a ...